• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Clostridium Difficile - Articles and news items

Report highlights need for improved management of CDI in IBD patients

Industry news / 11 April 2016 / Victoria White, Digital Content Producer

A current lack of data on outcomes in patients with IBD who have CDI means that appropriate choice of treatment strategy can be unclear…

MGB Biopharma completes Phase I trial of MGB-BP-3

Industry news / 8 December 2015 /

MGB-BP-3 is an antibiotic that is being developed for the potential treatment of Clostridium difficile infections…

Global Clostridium difficile infections market to hit $1.5b by 2024

Industry news / 23 October 2015 / Victoria White

GlobalData says this increase will be driven by the modest uptake of patent-protected, Clostridium difficile infection-specific antibiotics and the arrival of novel non-antibiotic approaches…

Bezlotoxumab reduces C. difficile infection recurrence in Phase 3 trials

Industry news / 21 September 2015 / Victoria White

Merck plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the US, EU and Canada in 2015…

Phase I clinical trial of oral formulation of MGB-BP-3 for treatment of Clostridium Difficile infections begins

Industry news / 21 July 2015 / Victoria White

The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3…

First patient dosed in the Phase 2 study of SER-109 in recurrent Clostridium difficile infection

Industry news / 28 May 2015 / Victoria White

Seres Therapeutics has enrolled and dosed the first patient in its Phase 2 clinical study of SER-109 in recurrent CDI in adults…

DIFICLIR (fidaxomicin) significantly reduces recurrence and all-cause mortality when used first-line in all patients diagnosed with Clostridium difficile infection (CDI)

Industry news / 21 May 2015 / Victoria White

Data presented from the Clostridium difficile Infection (CDI) Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes…